Immune Checkpoint Inhibitors Rechallenge Efficacy in Non–Small-Cell Lung Cancer Patients - Archive ouverte HAL
Article Dans Une Revue Clinical Lung Cancer Année : 2020

Immune Checkpoint Inhibitors Rechallenge Efficacy in Non–Small-Cell Lung Cancer Patients

1 CHUGA - Centre Hospitalier Universitaire [CHU Grenoble]
2 UNICANCER/CRCL - Centre de Recherche en Cancérologie de Lyon
3 Centre Léon Bérard [Lyon]
4 CHU Henri Mondor [Créteil]
5 HCL - Hospices Civils de Lyon
6 UCBL - Université Claude Bernard Lyon 1
7 CHU Nantes - Centre Hospitalier Universitaire de Nantes = Nantes University Hospital
8 UNICANCER/CRLC - Centre Régional de Lutte contre le Cancer François Baclesse [Caen]
9 CHRU Besançon - Centre Hospitalier Régional Universitaire de Besançon
10 CHU Toulouse - Centre Hospitalier Universitaire de Toulouse
11 CHU Rouen
12 CHU Bordeaux
13 CIC 1425 - Centre d'investigation Clinique [CHU Bichat] - Épidémiologie clinique
14 AP-HP - Hôpital Bichat - Claude Bernard [Paris]
15 Hôpital Ambroise Paré [AP-HP]
16 CHU Strasbourg - Centre Hospitalier Universitaire [Strasbourg]
17 Hôpital Cochin [AP-HP]
18 UNICANCER/Lille - Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille]
19 CHRU Brest - Centre Hospitalier Régional Universitaire de Brest
20 Centre Hospitalier Annecy-Genevois [Saint-Julien-en-Genevois]
21 CRCM - Centre de Recherche en Cancérologie de Marseille
22 APHM - Assistance Publique - Hôpitaux de Marseille
23 Institut Curie [Paris]
24 ICSC - Institut Curie - Saint Cloud
25 Institut de Cancérologie de la Loire Lucien Neuwirth
26 IGR - Institut Gustave Roussy
27 CHU Caen
28 CHU Tenon [AP-HP]
29 GRC 4 - Theranoscan - Groupe de recherche clinique Biomarqueurs Théranostiques des Cancers Bronchiques Non à Petites Cellules
30 Hôpitaux Paris Seine-Saint-Denis [Bobigny]
31 Centre Hospitalier Le Mans (CH Le Mans)
Florian Guisier
Rémi Veillon
  • Fonction : Auteur
Youssef Oulkhouir
  • Fonction : Auteur

Résumé

Background: Immune checkpoint inhibitor (ICPi) rechallenge could represent an attractive option in non-small-cell lung cancer (NSCLC), yet no sufficient data supporting this strategy are available. This retrospective observational multicenter national study explored the efficacy of anti-programmed cell death 1 (PD-1)/programmed death ligand 1 (PD-L1) rechallenge in advanced NSCLC patients, looking for potential clinical features associated with greater outcomes. Patients and methods: We retrospectively collected data from 144 advanced NSCLC patients whose disease was rechallenged with ICPis after ≥ 12 weeks of discontinuation. The progression-free survival (PFS) and overall survival (OS) were calculated from first or second ICPi initiation to disease progression (PFS1 and PFSR, respectively), death, or last follow-up (OS1, OSR), respectively. Results: The median (interquartile range) age was 63 (58-70) years. Most patients were male (67%) and smokers (87%). Most had adenocarcinomas (62%) and/or stage IV disease at diagnosis (66%). The best response at rechallenge was not associated with that under the first ICPi (P = 1.10-1). The median (95% confidence interval) PFS1 and PFSR were 13 (10-16.5) and 4.4 (3-6.5) months, respectively. The median (95% confidence interval) OS1 and OSR were 3.3 (2.9-3.9) and 1.5 (1.0-2.1) years, respectively. Longer PFSR and OSR were found in patients discontinuing first ICPi because of toxicity or clinical decision, those not receiving systemic treatment between the two ICPis, and those with good Eastern Cooperative Oncology Group performance status at rechallenge. Only performance status proved to affect outcomes at multivariate analysis. Conclusion: Patients discontinuing first ICPi because of toxicity or clinical decision, those able to maintain a treatment-free period, and those with good performance status may be potential candidates for rechallenge.

Domaines

Cancer

Dates et versions

hal-04728622 , version 1 (09-10-2024)

Identifiants

Citer

Elisa Gobbini, Anne Claire Toffart, Maurice Pérol, Jean-Baptiste Assié, Michaël Duruisseaux, et al.. Immune Checkpoint Inhibitors Rechallenge Efficacy in Non–Small-Cell Lung Cancer Patients. Clinical Lung Cancer, 2020, 21 (5), pp.e497-e510. ⟨10.1016/j.cllc.2020.04.013⟩. ⟨hal-04728622⟩
0 Consultations
0 Téléchargements

Altmetric

Partager

More